Authors
Latest:
Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRCAmanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.
Latest:
Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple MyelomaAmandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.
Latest:
Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCLAriel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.
Latest:
Extending the Frontiers of Checkpoint Inhibition in Merkel Cell CarcinomaIn the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.
Latest:
Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic CancerMatthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.
Latest:
Dr Badros on the Design of the AURIGA Study of Daratumumab/Lenalidomide in Newly Diagnosed MyelomaAshraf Z. Badros, MBCHB, discusses the design of the AURIGA trial of daratumumab plus lenalidomide in newly diagnosed myeloma following transplant.
Latest:
Dr Gehrig on the Use of Genetic Testing in Endometrial CancerPaola Gehrig, MD, discusses the optimal use and timing of genetic testing in endometrial cancer.
Latest:
Dr. Narkhede on Siltuximab for CRS and ICANS in Hematologic MalignanciesMayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.
Latest:
Unanswered Questions in HER2+ Breast CancerConsiderations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.
Latest:
Dr. Lin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCLRichard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Latest:
Dr Porter on the Potential Role for Taletrectinib in ROS1+ NSCLCJason Porter, MD, discusses the potential role of the next-generation TKI taletrectinib in patients with ROS1-positive non–small cell lung cancer, according to data from the phase 2 TRUST-II trial.
Latest:
Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate CancerVinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.
Latest:
Dr. Sandhu on Findings with Niraparib in Metastatic Prostate CancerShahneen Sandhu, MD, discusses findings with niraparib in metastatic prostate cancer from the phase 3 MAGNITUDE trial.
Latest:
How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MDDrs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.
Latest:
Dr. Roback on Subsequent Treatment Following Ibrutinib Discontinuation in CLLTadeusz Robak, MD, PhD, discusses subsequent treatment after discontinuation of ibrutinib on the phase 3 RESONATE-2 trial in patients with chronic lymphocytic leukemia.
Latest:
Assessing the Promise of AI in Oncology: Looking to the FutureIn this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.
Latest:
Dr. Ward on the Benefits of Delaying Salvage Therapy in Prostate CancerMatthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.
Latest:
Holistic and Multidisciplinary Approaches to Multiple Myeloma ManagementClosing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Latest:
Dr Franses on the Need for Prospective Data in Second-Line HCC and BeyondJoseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.
Latest:
Dr Kurz on Social Determinants of Health That Contribute to Disparities in Cancer CareRenee Kurz, DNP, FNP-BC, AOCNP, discusses social determinants of health that can contribute to disparities in cancer care, highlighting examples seen throughout New Jersey that emphasize the need for further investigation into this landscape.
Latest:
Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCCSaby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.
Latest:
Make Time for Your Own HealthAlthough graduate medical education at many hospitals includes provisions to ensure that trainees remain physically, emotionally, and mentally healthy, few residents and fellows make use of these resources.
Latest:
Undocumented Immigrants With Cancer Face Unique Care ChallengesUndocumented immigrants continue to face discriminatory policies, which affect those with cancer on emotional, financial, physical, and social levels.
Latest:
Dr Luo on Optimal Initial Chemotherapy Regimens in NUT CarcinomaJia Luo, MD, discusses a retrospective analysis of initial chemotherapy regimens for the treatment of patients with locally advanced and metastatic NUT carcinoma, which was presented at the 2023 IASLC World Conference on Lung Cancer.
Latest:
Dr Basin on the Methods for Investigating Hsp70 Inhibition in Belzutifan-resistant in RCCMichael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.
Latest:
Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung CancerEric Vail, MD, discusses emerging advances in biomarker testing in lung cancer.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
Emerging Concepts on the Role of Immunotherapy in NSCLCMartin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.
.jpg?fit=crop&auto=format)
